Symbols

MASI

Masimo·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MASI

Masimo Corporation

A global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

08/07/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

3,600

Fiscal Year Ends

12-31

Website

www.masimo.com

Security Type

Common stock

Office address

52 Discovery, Irvine, CA 92618

Business

Introduction

Masimo Corporation was incorporated in California in May 1989 and re-incorporated in Delaware in May 1996. The Company is a global medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The company's mission is to improve patient outcomes and reduce care costs by bringing non-invasive monitoring to new sites and applications. The company invented the Masimo signal extraction technology, Masimo SET, which provides the ability to measure movement and low perfusion pulse oximeters to address the main limitations of traditional pulse oximeters. Pulse oximeters are non-invasive measures of arterial oxygen saturation levels, or the blood that delivers oxygen to human tissue, as well as pulse frequency. Pulse oximeters are one of the most common measurements taken in and out of hospitals around the world. Validated in more than 100 independent clinical studies, Masimo SET is the only pulse oximeter technology known to the company that has been shown to help clinicians detect critical congenital heart disease in newborns, reduce retinopathy in preterm newborns, and reduce intensive care unit metastases and rapid response activation on general floors. The company's products include a monitor or circuit board for its proprietary single-patient use and reusable sensors and cables. The Company sells its products to end users through its direct sales force and certain distributors, and sells some of the Company's products to its original equipment manufacturers or OEM partners for inclusion in products.

Earnings Call

Q1/2025

Estimate EPS1.21

Actual EPS1.36

Estimate Revenue367.79M

Actual Revenue372.00M

Masimo's Q1 2025: Key Contradictions in Tariff Strategies, Healthcare Growth, and Margin Expectations

May 13,2025 04:51·
Earnings Decrypt

Q2/2025

Estimate EPS1.22

Actual EPS1.33

Estimate Revenue368.65M

Actual Revenue371.00M

Masimo's Q2 2025 Earnings Call: Unpacking Contradictions in Hospital Demand, Cybersecurity, and Tariff Strategies

Aug 05,2025 11:14·
Earnings Decrypt

Company Financials

EPS

MASI has released its 2025 Q3 earnings. EPS was reported at 1.32, versus the expected 1.2, beating expectations. The chart below visualizes how MASI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MASI has released its 2025 Q3 earnings report, with revenue of 371.50M, reflecting a YoY change of 8.21%, and net profit of -100.40M, showing a YoY change of -1124.49%. The Sankey diagram below clearly presents MASI's revenue sources and cost distribution.